Janusz Jaworski Selected Research

CT-P17

11/2022	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.
1/2021	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janusz Jaworski Research Topics

Disease

8	Rheumatoid Arthritis 11/2022 - 02/2017
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2019 - 06/2016
1	Psoriatic Arthritis 06/2016
1	Ankylosing Spondylitis 01/2016

Drug/Important Bio-Agent (IBA)

6	Biosimilar PharmaceuticalsIBA 01/2021 - 02/2017
4	Adalimumab (Humira)FDA Link 11/2022 - 01/2018
3	CT-P13IBA 01/2021 - 01/2016
2	CT-P17IBA 11/2022 - 01/2021
2	Antirheumatic Agents (DMARD)IBA 01/2019 - 06/2016
2	Infliximab (Remicade)FDA Link 02/2017 - 01/2016
1	Citric Acid (Citrate)FDA LinkGeneric 01/2021
1	Rituximab (Mabthera)FDA Link 02/2019
1	CT-P10IBA 02/2019
1	GP2015IBA 01/2019
1	Etanercept (Enbrel)FDA Link 01/2019
1	Biological ProductsIBA 06/2016
1	Phosphodiesterase 4 InhibitorsIBA 06/2016
1	apremilastIBA 06/2016

Therapy/Procedure

1	Therapeutics 06/2016